(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 August 2013 (22.08.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/123419 A1

(51) **International Patent Classification**:
A61K 31/4704 (2006.01)

(21) **International Application Number**:
PCT/US2013/026476

(22) **International Filing Date**:
15 February 2013 (15.02.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/599,680 16 February 2012 (16.02.2012) US

(71) **Applicant** *(for all designated States except BB, US)*: **TEVA PHARMACEUTICAL INDUSTRIES LTD.** [IL/IL]; 5 Basel Street, P.O. Box 3190, Petach Tikva 49131 (IL).

(71) **Applicant** *(for BB only)*: **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Horsham Road, North Wales, PA 19454 (US).

(72) **Inventors; and**
(71) **Applicants** *(for US only)*: **IOFFE, Vladimir** [IL/IL]; David-ha-Melech St., 13/2, Kfar Saba, 44430 (IL). **ULANENKO, Konstantin** [IL/IL]; Beeri St. 69/1, Netanya, 42258 (IL). **LAXER, Avital** [IL/IL]; Levi Eshkol St. 92/16, Tel-Aviv, 69361 (IL). **SAFADI, Muhammad** [IL/IL]; Panorama Salezian, 5A, Street 5005, P.O. Box 385, Nazareth, 16103 (IL). **LICHT, Danit** [IL/IL]; 1 Keren Hayesod Street, Ramat Ilan, Givat Shmuel, 54041 (IL). **LOVINGER, Ioana** [IL/IL]; Tel Hai St. 98/3, Kfar Saba, 44245 (IL). **FRISTEDT, Ulf, Tomas** [SE/SE]; Byalagsgatan 54, S-256 56 Helsingborg (SE).

(74) **Agent**: **WHITE, John, P.**; Cooper & Dunham LLP, 30 Rockefeller Plaza, New York, NY 10112 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2013/123419 A1

(54) **Title**: N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINE CARBOXAMIDE, PREPARATION AND USES THEREOF

(57) **Abstract**: The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1, 2-dihydro-4, 5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.